Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

加利福尼亚州卡尔斯巴德 - 专注于成纤维细胞生长因子受体(FGFR)相关疾病精准医疗的生物科技公司Tyra Biosciences, Inc. (NASDAQ:TYRA)宣布,美国食品和药物管理局(FDA)已批准其TYRA-300的新药研究申请(IND)。这一批准为针对儿童软骨发育不全症(一种常见的侏儒症)的二期临床试验铺平了道路。 TYRA-300是一种口服FGFR3选择性抑制剂,旨在解决当前治 ...

This work is an important contribution to understanding the role of FGF signaling in the induction of primitive-like cells in a 2D system of human gastrulation. The authors provide compelling evidence ...

In addition, they showed that treatment with R3Mab reduced the phosphorylation of FGFR substrate 2α and mitogen-activated protein kinase, indicating that FGFR3-mediated signalling was suppressed.

University of Auckland senior research fellow Jeff Smaill first visited China in 2012 as part of a team of 15 scientists from the Maurice Wilkins Center, one of New Zealand’s centers of excellence, to ...

Despite an outcome that TD Cowen analyst Tyler Van Buren called ”fantastic,” shares of Tyra Biosciences Inc. (NASDAQ:TYRA) closed Oct. 25 at $21.93, down $6.68, or 23%, as Wall Street digested new ...

Please note that following on from information provided to NICE by the company in January 2023, the appraisal was suspended from NICE’s work programme. As no further information has been received from ...

Multi-kinase inhibition by fexagratinib may offer a more comprehensive therapeutic approach than selective FGFR inhibition in ...

"In addition, we saw improved tolerability compared to pan-FGFR inhibitors, with lower rates of significant adverse side effects, such as increased phosphate in the blood, skin and eye reactions ...

Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision ...

The green light from the European Commission comes a few months after pan-FGFR inhibitor Balversa (erdafitinib) was cleared for the same indication in the US, with a different label than the drug ...